Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX)

Historical Holders from Q3 2016 to Q3 2025

Symbol
PTGX on Nasdaq
Type / Class
Equity / Common Stock, par value $0.00001
Shares outstanding
62.2M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
70.7M
Holdings value
$4.7B
% of all portfolios
0.008%
Grand Portfolio weight change
+0%
Number of holders
272
Number of buys
122
Number of sells
-149
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 13.8% -6.67% $570M -$33.8M 8.58M -5.6% BlackRock, Inc. 30 Sep 2025
Farallon Capital Partners, L.P. 9.99% $265M 5.96M Dapice Joshua J. 31 Dec 2024
STATE STREET CORP 5.2% +20% $170M $26.6M 3.21M +18.5% STATE STREET CORPORATION 30 Jun 2025
BIOTECHNOLOGY VALUE FUND L P 4.1% -22% $170M -$43.2M 2.56M -20.2% BVF PARTNERS L P/IL 30 Sep 2025
Deep Track Capital, LP 2.76% -50.6% $114M -$102M 1.72M -47.2% Deep Track Capital, LP 30 Sep 2025

Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 70.7M $4.7B +$3.94M $66.43 272
2025 Q2 71M $3.92B +$345M $55.27 273
2025 Q1 65M $3.14B +$116M $48.36 273
2024 Q4 63.3M $2.44B +$44.2M $38.60 240
2024 Q3 61.6M $2.77B -$40.5M $45.00 238
2024 Q2 59.1M $2.05B -$15.1M $34.65 187
2024 Q1 59.7M $1.73B +$80.4M $28.93 183
2023 Q4 57.5M $1.32B +$12.2M $22.93 155
2023 Q3 56.7M $946M -$53.3M $16.68 142
2023 Q2 56.7M $1.57B +$105M $27.62 163
2023 Q1 53.2M $1.22B +$180M $23.00 135
2022 Q4 49M $535M +$12.4M $10.91 135
2022 Q3 47.3M $399M -$50.1M $8.43 129
2022 Q2 53.4M $422M -$73.7M $7.91 125
2022 Q1 50.3M $1.19B -$6.17M $23.68 136
2021 Q4 49.2M $1.68B +$93.5M $34.20 144
2021 Q3 46.2M $819M -$247M $17.72 126
2021 Q2 48M $2.15B +$180M $44.88 136
2021 Q1 44.2M $1.14B +$27.8M $25.90 124
2020 Q4 43M $867M +$98.8M $20.16 124
2020 Q3 37.2M $727M +$62.1M $19.55 91
2020 Q2 34M $601M +$210M $17.66 82
2020 Q1 23.4M $165M +$1.23M $7.06 75
2019 Q4 23.2M $164M +$7.87M $7.05 79
2019 Q3 18.9M $228M +$20.6M $12.01 74
2019 Q2 17.2M $208M +$26M $12.11 66
2019 Q1 15.1M $189M +$21.7M $12.57 64
2018 Q4 13.9M $93.2M -$9.99M $6.73 62
2018 Q3 16M $165M +$26.8M $10.29 60
2018 Q2 13.9M $93.6M +$10.9M $6.72 68
2018 Q1 11.9M $103M -$12M $8.59 67
2017 Q4 11.8M $246M +$77.2M $20.80 64
2017 Q3 8.13M $144M +$619K $17.67 41
2017 Q2 8.12M $91.8M -$277K $11.31 40
2017 Q1 8.01M $103M +$4.47M $12.81 39
2016 Q4 7.98M $175M +$2.37M $21.99 38
2016 Q3 6.9M $145M +$145M $21.13 34